LUMINAL B IS THE MOST COMMON BREAST CANCER SUBTYPE IN PATIENTS OF ALMATY ONCOLOGY CENTER
Introduction: Breast cancer is a heterogenous group of disease that is most prevalent malignant disease of female population of Kazakhstan.
Aim of study: to find most common pathologic type and molecular subtype of breast cancer cases in the Almaty oncology center and evaluate association among molecular subtype with different pathological type, tumor characteristics and Participant’s criteria
Materials and methods: A cross sectional study was conducted at Almaty oncology center, Kazakhstan between January and December 2020. We studied medical records of 818 breast cancer cases and included data of 622 cases in this study. Data about pathologic type, grade, stage, estrogen (ER), progesterone (PR) HER2 overexpression and ki67 were analyzed. Molecular subtype determination in this center was done by using immunohistochemistry and this Criteria (‘Luminal A-like’ ER/PR +, HER2-, Ki67 low) (‘Luminal B-like' ER/PR +, HER2 ± and Ki67 high) (‘HER2-positive’ HER2+ ER and PR -) (Triple-negative ER and PR absent HER2-). The association were evaluated among molecular subtype with different pathological type, tumor characteristics and Participant’s criteria using Chi square test
Results: Most common pathologic type of tumor in this study was NST (85.3%), ILC (3.8%) and DCIS (2.1%) respectively. Most prevalent molecular subtype of tumors: Luminal B (57.6%), luminal A (22.2%), triple negative (12%) and HER/2 enriched (8.3%). There was statistically significant association (p-value <0.05) between Molecular subtype and pathologic type of tumor, grade, stage, size, hormone receptors, HER/2 over expression and mitotic rate.
Conclusion: luminal B was the most prevalent subtype and HER2 positive was the least prevalent and it is better to work more for finding better treatment for luminal B. A significant association among molecular subtype of tumor and pathologic subtype, grade, stage, size, hormone receptors, HER/2 over expression and mitotic rate were found.
Maryam Zabihi 1, Mahboba Islami 2,
Natalya Glushkova 3, https://orcid.org/0000-0003-1400-8436, Ainash Altayeva 4
1 Herat University, Medical Faculty, Department of histopathology, Herat, Afghanistan;
2 Kabul University of Medical science, Department of anesthesiology, Kabul, Afghanistan;
3 Al-Farabi Kazakh National University, Department of Epidemiology, Biostatistics & Evidence Based Medicine, Almaty, Republic of Kazakhstan;
4 Al-Farabi Kazakh National University, Department of Clinical Disciplines, Almaty, Republic of Kazakhstan.
1. Azamjah N., Soltan-Zadeh Y., Zayeri F. Global trend of breast cancer mortality rate: A 25-year study // Asian Pacific J. Cancer Prev. 2019. Vol. 20, № 7. P. 2015–2020.
2. Abe O. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials // Lancet. Elsevier Ltd, 2011. Vol. 378, № 9793. P. 771–784.
3. Globocan Observatory 2019 W.I., (IARC) I.A. for R. on C., (WHO) W.H.O. Breast Cancer. Source: Globocan 2018 // World Heal. Organ. Int. Agency Res. Cancer. 2019. Vol. 876. P. 2018–2019.
4. Igissinov N. et al. Breast cancer in megapolises of Kazakhstan: Epidemiological assessment of incidence and mortality // Iran. J. Public Health. 2019. Vol. 48, № 7. P. 1257–1264.
5. Pokazateli onkologicheskoi sluzhby Respubliki Kazahstan za 2019 god. [Electronic resource]. URL: https://onco.kz/wp-content/uploads/2021/02/Pokazateli-onkologicheskoj-sluzhby-Respubliki-Kazahstan-za-2019-g_09.02.2021_compressed-1.pdf (accessed: 07.06.2021).
6. Kaidarova D., Zhylkaidarova A., Saktaganov M. 12-Years results of the Kazakhstan breast cancer screening programme. 2020. Vol. 30, № Suppl 4. P. 3–4.
7. Moschetta M. et al. Comparison between fine needle aspiration cytology (FNAC) and core needle biopsy (CNB) in the diagnosis of breast lesions // G. di Chir. 2014. Vol. 35, № 7–8. P. 171–176.
8. Han E.S., goleman, daniel; boyatzis, Richard; Mckee A. biopsy interpretation of breast // wolters kluer. 3rd ed. wolters kluwer, 2019.
9. Ohm V.D. et al. WHO classification of Tumors. Breast Tumours // Breast Tumours. 2019. 284 p.
10. Allison K.H. et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update // J. Clin. Oncol. 2020. Vol. 38, № 12. P. 1346–1366.
11. Wolff A.C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/ college of American pathologists clinical practice guideline focused update // J. Clin. Oncol. 2018. Vol. 36, № 20. P. 2105–2122.
12. Abiltayeva A. et al. Clinical, Histopathological and Molecular Characteristics of Metastatic Breast Cancer in North-Eastern Kazakhstan: a 10 Year Retrospective Study // Asian Pacific J. Cancer Prev. 2016. Vol. 17, № 10. P. 4797–4802.
13. Al-thoubaity F.K. Molecular classification of breast cancer: A retrospective cohort study // Ann. Med. Surg. 2020. Vol. 49, № October 2019. P. 44–48.
14. Caldarella A. et al. Invasive breast cancer: A significant correlation between histological types and molecular subgroups // J. Cancer Res. Clin. Oncol. 2013. Vol. 139, № 4. P. 617–623.
15. Badowska-Kozakiewicz A.M. et al. The role of oestrogen and progesterone receptors in breast cancer - Immunohistochemical evaluation of oestrogen and progesterone receptor expression in invasive breast cancer in women // Wspolczesna Onkol. 2015. Vol. 19, № 3. P. 220–225.
16. Thang V.H. et al. Cell proliferation measured by Ki67 staining and correlation to clinicopathological parameters in operable breast carcinomas from vietnamese and Swedish patients // J. Anal. Oncol. 2015. Vol. 4, № 2. P. 58–68.
17. Mandaliya H.A. et al. Breast cancer demographics, screening and survival outcome at a regional Australian cancer centre: a retrospective study // Ann. Oncol. Elsevier Masson SAS, 2016. Vol. 27, № Supplement 6. P. vi479.
18. El Fatemi H. et al. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: An immunohistochemical profile study from Morocco // Diagn. Pathol. Diagnostic Pathology, 2012. Vol. 7, № 1. P. 1.
19. San T.H. et al. Molecular subtypes of breast cancers from Myanmar women: A study of 91 cases at two pathology centers // Asian Pacific J. Cancer Prev. 2017. Vol. 18, № 6. P. 1617–1621.
20. Paramita S. et al. Luminal B is the most common intrinsic molecular subtypes of invasive ductal breast carcinoma patients in East Kalimantan, Indonesia // Asian Pacific J. Cancer Prev. 2019. Vol. 20, № 8. P. 2247–2252.
21. Setyawati Y. et al. The association between molecular subtypes of breast cancer with histological grade and lymph node metastases in Indonesian woman // Asian Pacific J. Cancer Prev. 2018. Vol. 19, № 5. P. 1263–1268.
22. Li J. et al. Clinicopathological classification and traditional prognostic indicators of breast cancer // Int. J. Clin. Exp. Pathol. 2015. Vol. 8, № 7. P. 8500–8505.
23. Hashmi A.A. et al. Molecular subtypes of breast cancer in south Asian population by immunohistochemical profile and her2neu gene amplification by fish technique: Association with other clinicopathologic parameters // Breast J. Blackwell Publishing Inc., 2014. Vol. 20, № 6. P. 578–585.
24. Liu Y.H. et al. Unexpected features of breast cancer subtype // World J. Surg. Oncol. World Journal of Surgical Oncology, 2015. Vol. 13, № 1. P. 1–5.
25. Zavyalova M. et al. Clinicopathological features of nonspecific invasive breast cancer according to its molecular subtypes // Exp. Oncol. 2016. Vol. 38, № 2. P. 122–127.
26. Mehdi I., Abdulmasood A. a., Al Bahrani B.J. Breast cancer molecular subtypes in Omani patients: Correlation with age, histology, stage distribution, and outcome—An anaylsis of 542 cases. // J. Clin. Oncol. 2011. Vol. 29, № 27_suppl. P. 219–219.
27. Alnegheimish N.A. et al. Molecular subtypes of breast carcinoma in Saudi Arabia: A retrospective study // Saudi Med. J. 2016. Vol. 37, № 5. P. 506–512.
Количество просмотров: 358
Категория статей:
Оригинальные исследования
Библиографическая ссылка
Zabihi M., Islami M., Glushkova N., Altayeva A. Luminal B is the most common breast cancer subtype in patients of Almaty oncology center // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, (Vol.23) 5, pp. 93-100. doi 10.34689/SH.2021.23.5.011Похожие публикации:
МЕХАНИКАЛЫҚ САРҒАЮ ОПЕРАЦИЯСЫ КЕЗІНДЕ КОАГУЛОПАТИЯЛЫҚ ҚАН КЕТУДІҢ АЛДЫН АЛУ ӘДІСІ
ОПТИМИЗАЦИЯ РЕЗУЛЬТАТОВ АУТОДЕРМОПЛАСТИКИ ПРИ ЛЕЧЕНИИ ГРАНУЛИРУЮЩИХ ГНОЙНЫХ РАН
BASICS OF REHABILITATION OF CHILDREN AFTER OPERATIONS ON THE COLON AND ANORECTAL AREA
HEALTH INDICATORS OF FIRST-YEAR-OF-LIFE CHILDREN IN THE REPUBLIC OF KAZAKHSTAN FOR 2013-2022
ОЦЕНКА УДОВЛЕТВОРЕННОСТИ ТРУДОВОЙ ДЕЯТЕЛЬНОСТЬЮ ВРАЧЕЙ АНЕСТЕЗИОЛОГОВ-РЕАНИМАТОЛОГОВ ГОРОДА АСТАНА